Skip to main content
logo
Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.120
+0.010 (0.47%)
At close: Aug 11, 2026, 4:00 PM EDT
2.130
+0.010 (0.47%)
Pre-market: Aug 12, 2026, 8:00 AM EDT

Grace Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
-7.79-9.57-12.85-42.43-9.82
Depreciation & Amortization
0.010.010.010.12-
Stock-Based Compensation
0.80.730.911.811.34
Other Adjustments
-2.6-6.420.8824.4-5.97
Change in Receivables
0.110.60.08-0.3-
Changes in Accounts Payable
0.54-0.08-1.650.41-
Changes in Other Operating Activities
0.07-0.170.290.07-2.79
Operating Cash Flow
-8.87-14.9-12.33-15.91-17.23
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
---0.02-0.02-
Sale of Property, Plant & Equipment
--0.11--
Purchases of Investments
--0.02-6.55-5.02-34.93
Proceeds from Sale of Investments
-0.026.5718.1931.41
Investing Cash Flow
-00.113.15-3.52

Financing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Issuance of Common Stock
4.04157.360.3-
Repurchase of Common Stock
-0.33-0.97---
Net Common Stock Issued (Repurchased)
3.7114.037.360.3-
Financing Cash Flow
3.7114.037.360.3-

Net Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
----0.010.15
Net Cash Flow
-5.16-0.87-4.87-2.46-20.6

Free Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
-8.87-14.9-12.36-15.93-17.23
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-0.54-1.23-1.30-2.14-2.81
Levered Free Cash Flow
-7.17-9.82-14.22-41.84-12.61
Unlevered Free Cash Flow
-10.46-16.93-12.62-41.99-17.41
SEC Filings: 10-K · 10-Q